Evidence map›Paper›PMID 34125339›Full record

ArticleBreast cancer research and treatment2021

Impact of HIV infection on overall survival among women with stage IV breast cancer in South Africa.

Yoanna S Pumpalova, Oluwatosin A Ayeni, Wenlong Carl Chen, Daniel S O'Neil, Sarah Nietz, Boitumelo Phakathi, Ines Buccimazza, Sharon Čačala, Laura W Stopforth, Hayley A Farrow and 7 more

Open access · greenAbstract read
In one paragraph

Article in Breast cancer research and treatment, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Navigating the Nexus: HIV and Breast Cancer-A Critical Review.International journal of molecular sciences · 2024
    Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 2 countries.

Yoanna S PumpalovaDepartment of Medicine, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA.
Oluwatosin A AyeniNoncommunicable Diseases Research Division, Wits Health Consortium (PTY) Ltd, Johannesburg, South Africa.
Wenlong Carl ChenNoncommunicable Diseases Research Division, Wits Health Consortium (PTY) Ltd, Johannesburg, South Africa.
Daniel S O'NeilSylvester Comprehensive Cancer Center and Department of Medicine, Miller School of Medicine, University of Miami, Miami, FL, USA.
Sarah NietzNoncommunicable Diseases Research Division, Wits Health Consortium (PTY) Ltd, Johannesburg, South Africa.
Boitumelo PhakathiNoncommunicable Diseases Research Division, Wits Health Consortium (PTY) Ltd, Johannesburg, South Africa.
Ines BuccimazzaNoncommunicable Diseases Research Division, Wits Health Consortium (PTY) Ltd, Johannesburg, South Africa.
Sharon ČačalaNoncommunicable Diseases Research Division, Wits Health Consortium (PTY) Ltd, Johannesburg, South Africa.
Laura W StopforthNoncommunicable Diseases Research Division, Wits Health Consortium (PTY) Ltd, Johannesburg, South Africa.
Hayley A FarrowNoncommunicable Diseases Research Division, Wits Health Consortium (PTY) Ltd, Johannesburg, South Africa.
Maureen JoffeNoncommunicable Diseases Research Division, Wits Health Consortium (PTY) Ltd, Johannesburg, South Africa.
Witness MapangaNoncommunicable Diseases Research Division, Wits Health Consortium (PTY) Ltd, Johannesburg, South Africa.
Judith S JacobsonHerbert Irving Comprehensive Cancer Center, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA.
Katherine D CrewDepartment of Medicine, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA.
Herbert CubaschNoncommunicable Diseases Research Division, Wits Health Consortium (PTY) Ltd, Johannesburg, South Africa.
Paul RuffNoncommunicable Diseases Research Division, Wits Health Consortium (PTY) Ltd, Johannesburg, South Africa.
Alfred I NeugutDepartment of Medicine, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA. ain1@columbia.edu.
University of the Witwatersrand · ZAColumbia University · USUniversity of KwaZulu-Natal · ZASouth African Medical Research Council · ZAAfrica Health Research Institute · ZAUniversity of Miami · US

Funding

Tumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Parisa Tehranifar · 1985 to 2026
$115.3M
UM Calabresi Clinical Oncology Research Career Development AwardK12CA226330 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Alan Pollack · 2018 to 2026
$5.1M
Novel predictors of survival among breast cancer patients with/without HIV in South AfricaR01CA250012 · NCI · WITS HEALTH CONSORTIUM (PTY), LTD · PI CUBASCH, HERBERT, EL-SADR, WAFAA M. · 2020 to 2024
$2.0M
HIV's Effects on Breast Cancer Treatment and Outcomes in South AfricaR01CA192627 · NCI · WITS HEALTH CONSORTIUM (PTY), LTD · PI JACOBSON, JUDITH S, JOFFE, MAUREEN · 2015 to 2019
$1.7M
Training Program in Cancer-related Population SciencesT32CA094061 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI NEUGUT, ALFRED I., TERRY, MARY BETH · 2017 to 2021
$1.1M
NCI NIH HHS K12 CA226330NCI NIH HHS K12CA226330NCI NIH HHS P30 CA013696NCI NIH HHS P30 CA13696NCI NIH HHS R01 CA192627NCI NIH HHS R01CA192627NCI NIH HHS R01 CA250012NCI NIH HHS R01CA250012NCI NIH HHS T32 CA094061
6 · The paper itself

Abstract

purposeAdvanced breast cancer (BC) at diagnosis is common in sub-Saharan Africa (SSA), including among women living with HIV (WLWH). In public hospitals across South Africa (SA), 10-15% of women present with stage IV BC, compared to < 5% in the United States (US); 20% of new BC diagnoses in SA are in WLWH. We evaluated the impact of HIV on overall survival (OS) among women with stage IV BC.

methodsWe conducted a prospective cohort study of women diagnosed with stage IV BC between February 2, 2015 and September 18, 2019 at six public hospitals in SA. Multivariate Cox regression models were used to estimate the association between HIV status and OS.

resultsAmong 550 eligible women, 147 (26.7%) were WLWH. Compared to HIV-negative BC patients, WLWH were younger (median age 45 vs. 60 years, p < 0.001), predominantly black (95.9% vs. 77.9%, p < 0.001), and more likely to have hormone receptor-negative (hormone-negative) BC (32.7% vs. 22.6%, p = 0.016). Most women received systemic cancer-directed therapy (80.1%). HIV status was not associated with treatment or OS (Hazard Ratio (HR) 1.13 [95%CI 0.89-1.44]). On exploratory subgroup analysis, WLWH and hormone-negative BC had shorter OS compared to HIV-uninfected women (1-year OS: 27.1% vs. 48.8%, p = 0.003; HR 1.94 [95%CI 1.27-2.94]; p = 0.002), which was not observed for hormone receptor-positive BC.

conclusionHIV status was not associated with worse OS in women with stage IV BC in SA and cannot account for the poor survival in this cohort. Subgroup analysis revealed that WLWH with hormone-negative BC had worse OS, which warrants further investigation.

Indexed as

Breast NeoplasmsHIV InfectionsCohort StudiesFemaleHumansMiddle AgedProspective StudiesSouth AfricaUnited StatesBreast cancerHIVMetastaticsub-Saharan Africa

Identifiers

PMID34125339
PMCPMC9034410
OpenAlexW3169712857

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.